(Photo: Yonhap News)
South Korean pharmaceutical firm Celltrion Inc. is expected to release the outcome of its second phase clinical study of a COVID-19 monoclonal antibody treatment later next week.
The Ministry of Food and Drug Safety is currently reviewing conditional approval of CT-P59, also known as Regdanvimab, which could potentially lead to manufacturing and sales of Korea's first homegrown coronavirus treatment.
Celltrion said Tuesday that data from its global phase two clinical trial will likely be presented during a forum slated for January 13.
The trial enrolled 327 patients with mild-to-moderate symptoms of COVID-19 to evaluate the efficacy and safety of CT-P59 in combination with standard of care treatment.
The company has said its drug shortened the recovery time of patients with no reported side effects, and killed the coronavirus within 4-5 days, effectively protecting patients with mild symptoms from developing into severe cases.
Celltrion earlier said it plans to initiate a global phase three clinical trial in more than 10 countries to obtain more comprehensive safety and efficacy data and will submit an application for emergency use in the U.S. and Europe in the coming months.
Please send comments to tbsefmnews@gmail.com / copyright © tbs. Unauthorized redistribution prohibited.
